FOI Reference: FOI 414 - 2021

Home , Binimetinib, Encorafenib, Trametinib, Vemurafenib

Title: Researching the Incidence and Treatment of Melanoma and Breast Cancer

Date: February 2021

FOI Category: Pharmacy

FOI Request:

1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+?

2. In the past 3 months, how many melanoma patients (any stage) were treated with the following:

• Cobimetinib • Dabrafenib • Dabrafenib AND Trametinib • Encorafenib AND Binimetinib • Ipilimumab • Ipilimumab AND Nivolumab • Nivolumab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib AND Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only

3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY:

• Ipilimumab • Ipilimumab AND Nivolumab • Nivolumab • Pembrolizumab • Any other therapies

4. In the past 3 months how many patients were treated with the following for breast cancer?

• Abemaciclib + Anastrozole/Exemestane/Letrozole • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Atezolizumab • Bevacizumab

[Type text]

• Eribulin • Everolimus + Exemestane • Fulvestrant as a single agent • Gemcitabine + Paclitaxel • Lapatinib • Neratinib • Olaparib • Palbociclib + Anastrozole/Exemestane/Letrozole • Palbociclib + Fulvestrant • Pertuzumab + Trastuzumab + Docetaxel • Ribociclib + Anastrozole/Exemestane/Letrozole • Ribociclib + Fulvestrant • Talazoparib • Transtuzumab + Paclitaxel • Transtuzumab as a single agent • Trastuzumab emtansine • Any other active systemic anti-cancer therapy

FOI Response:

1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+? 0 2. In the past 3 months, how many melanoma patients (any stage) were treated with the following:  Cobimetinib  Dabrafenib  Dabrafenib AND Trametinib  Encorafenib AND Binimetinib  Ipilimumab  Ipilimumab AND Nivolumab  Nivolumab  Pembrolizumab  Trametinib  Vemurafenib  Vemurafenib AND Cobimetinib  Other active systemic anti-cancer therapy  Palliative care only

0 patients were treated with the above

3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY:  Ipilimumab  Ipilimumab AND Nivolumab

[Type text]

 Nivolumab  Pembrolizumab  Any other therapies

0 patients were treated with the above

4. In the past 3 months how many patients were treated with the following for breast cancer? Abemaciclib + Anastrozole/Exemestane/Letrozole 0 Abemaciclib + Fulvestrant 0 Alpelisib + Fulvestrant 0 Atezolizumab 0 Bevacizumab 0 Eribulin <5 Everolimus + Exemestane <5 Fulvestrant as a single agent 0 Gemcitabine + Paclitaxel 0 Lapatinib 0 Neratinib 0 Olaparib 0 Palbociclib + Anastrozole/Exemestane/Letrozole 15 Palbociclib + Fulvestrant <5 Pertuzumab + Trastuzumab + Docetaxel 5 Ribociclib + Anastrozole/Exemestane/Letrozole 0 Ribociclib + Fulvestrant 0 Talazoparib 0 Transtuzumab + Paclitaxel 0 Transtuzumab as a single agent <5 Trastuzumab emtansine <5 Any other active systemic anti-cancer therapy 46

Additional Information/Documents:

The Trust has suppressed some of the numbers within our response as it relates to a small geographical area and due to the low numbers of individuals involved. We are unable to provide the information requested as it constitutes personal data relating to an identifiable individual, disclosure of which would be in contravention of the principles set out in EU General Data Protection Regulations 2016 (GDPR) and UK Data Protection Act 2018 (DPA).

In particular, Principle (a) states that: Personal data shall be processed lawfully, fairly and in a transparent manner in relation to individuals and in particular, shall not be processed unless at least one of the lawful bases for processing set out in Article 6 GDPR is met and in the case of special category personal data, at least one of the lawful bases for processing

[Type text]

set out in Article 9 GDPR is met. In this case, the Trust, as a public authority, is under a legal obligation (Article 6(1)(c) GDPR to process the information to ensure it complies with its statutory obligations under the Freedom of Information Act. However, the Trust does not have a lawful basis to process the requested special category personal data under Article 9 GDPR and it is considered that disclosure would not be lawful or in line with Principle (a) for the following specified reasons:  the information relates to a small geographical area  disclosure, given the sensitivity of the information, could cause significant distress to those involved  individuals have a reasonable level of expectation that their personal medical information provided in confidence will not be disclosed  disclosure of the information and descriptions broken down as requested could enable them (or their close contacts/families) to self-identify the individual from that data. After due consideration given to this matter, we therefore decline to disclose the information as requested, applying the exemption under sections 40 (2) and 40 (3) (a) (i) of the Freedom of Information Act 2000.

[Type text]